Literature DB >> 34851442

[Polymyalgia rheumatica in 18-fluorodeoxyglucose-positron-emission-tomography/computed tomography : Improvement in diagnostic accuracy and differentiation from rheumatoid arthritis].

F Witte1, H-J Lakomek2, J Holzinger3, W-D Reinbold3.   

Abstract

BACKGROUND: The diagnosis of patients with polymyalgia rheumatica (PMR) has relied upon the clinical examination of symptoms and laboratory parameters of inflammation until now. Currently, the use of different imaging modalities is being explored, including ultrasound, MRI and PET.
OBJECTIVES: The aim was to evaluate the diagnostic value of 18-fluorodeoxyglucose-positron-emission-tomography/computed tomography (18F-FDG-PET/CT) for PMR, in order to improve the sensitivity and specificity of diagnosing PMR and to improve the differential diagnosis of rheumatoid arthritis (RA).
MATERIALS AND METHODS: Examinations using 18F-FDG-PET/CT of 284 rheumatological patients, including 97 patients with PMR, were retrospectively evaluated over a 44-month period. Furthermore, 13 regions changed by inflammation were analysed via a three-dimensional region of interest (ROI) measurement with determination of maximum standardized uptake values (SUVmax), followed by statistical analyses. RESULTS AND DISCUSSION: Patients with PMR presented significantly elevated uptake in all regions examined (p < 0.001), compared with a control group treated for rheumatological diseases. The method with the highest diagnostic relevance was represented by the combination of four SUVmax values of both anterolateral hip capsules and both ischial tuberosities, reaching a sensitivity of 91.3% and a specificity of 97.6% with a cut-off of 11.0 SUV at the initial diagnosis of PMR patients who had not yet received any immunosuppressive therapy. Patients with RA could be significantly distinguished from those with PMR at initial diagnosis in the same anatomical regions (p < 0.001).
© 2021. The Author(s).

Entities:  

Keywords:  Diagnosis; Giant cell arteritis; Glucocorticoids; Inflammation; Rheumatoid arthritis

Year:  2021        PMID: 34851442     DOI: 10.1007/s00393-021-01133-w

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  4 in total

1.  Evidence for synovitis in active polymyalgia rheumatica: sonographic study in a large series of patients.

Authors:  Bruno Frediani; Paolo Falsetti; Lara Storri; Stefania Bisogno; Fabio Baldi; Valeria Campanella; Caterina Acciai; Georgios Filippou; Francesca Chellini; Roberto Cosentino; Roberto Marcolongo
Journal:  J Rheumatol       Date:  2002-01       Impact factor: 4.666

Review 2.  Polymyalgia rheumatica: clinical update.

Authors:  Faisal Ameer; Julian McNeil
Journal:  Aust Fam Physician       Date:  2014-06

3.  Polymyalgia Rheumatica Revealing a Lymphoma: A Two-Case Report.

Authors:  Frank Verhoeven; Xavier Guillot; Mickaël Chouk; Clément Prati; Daniel Wendling
Journal:  Case Rep Rheumatol       Date:  2016-08-11

4.  The Utility of 18F-FDG PET/CT in Patients With Clinical Suspicion of Polymyalgia Rheumatica and Giant Cell Arteritis: A Prospective, Observational, and Cross-sectional Study.

Authors:  Amir Emamifar; Torkell Ellingsen; Søren Hess; Oke Gerke; Rasmus Hviid Larsen; Ziba Ahangarani Farahani; Per Syrak Hansen; Inger Marie Jensen Hansen; Henrik Petersen; Niels Marcussen; Michael Dahlstrøm; Pia Toftegaard; Peter Thye-Rønn
Journal:  ACR Open Rheumatol       Date:  2020-07-22
  4 in total
  1 in total

1.  [Rheumatology centers according to the regulations of the Federal Joint Committee].

Authors:  Heinz-Jürgen Lakomek; Wolfgang Fiori
Journal:  Z Rheumatol       Date:  2022-09-28       Impact factor: 1.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.